292 related articles for article (PubMed ID: 28887232)
1. Dry powder inhalers: An overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products.
Velaga SP; Djuris J; Cvijic S; Rozou S; Russo P; Colombo G; Rossi A
Eur J Pharm Sci; 2018 Feb; 113():18-28. PubMed ID: 28887232
[TBL] [Abstract][Full Text] [Related]
2. In vitro dissolution testing of respirable size anti-tubercular drug particles using a small volume dissolution apparatus.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2019 Mar; 559():235-244. PubMed ID: 30684598
[TBL] [Abstract][Full Text] [Related]
3. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
4. Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs.
Malmlöf M; Nowenwik M; Meelich K; Rådberg I; Selg E; Burns J; Mascher H; Gerde P
Eur J Pharm Biopharm; 2019 Jun; 139():213-223. PubMed ID: 30862480
[TBL] [Abstract][Full Text] [Related]
5. Electrohydrodynamic methods for the development of pulmonary drug delivery systems.
Nikolaou M; Krasia-Christoforou T
Eur J Pharm Sci; 2018 Feb; 113():29-40. PubMed ID: 28865687
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model.
Eriksson J; Thörn H; Sjögren E; Holmstén L; Rubin K; Lennernäs H
Mol Pharm; 2019 Jul; 16(7):3053-3064. PubMed ID: 31136181
[TBL] [Abstract][Full Text] [Related]
7. Low powder mass filling of dry powder inhalation formulations.
Eskandar F; Lejeune M; Edge S
Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
[TBL] [Abstract][Full Text] [Related]
8. The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers.
Buttini F; Rozou S; Rossi A; Zoumpliou V; Rekkas DM
Eur J Pharm Sci; 2018 Feb; 113():64-76. PubMed ID: 29104067
[TBL] [Abstract][Full Text] [Related]
9. Aerosolization, Drug Permeation and Cellular Interaction of Dry Powder Pulmonary Formulations of Corticosteroids with Hydroxypropyl-β-Cyclodextrin as a Solubilizer.
Vartiainen V; Bimbo LM; Hirvonen J; Kauppinen EI; Raula J
Pharm Res; 2017 Jan; 34(1):25-35. PubMed ID: 27604893
[TBL] [Abstract][Full Text] [Related]
10. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
11. Dry powder inhaler formulation comparison: Study of the role of particle deposition pattern and dissolution.
Noriega-Fernandes B; Malmlöf M; Nowenwik M; Gerde P; Corvo ML; Costa E
Int J Pharm; 2021 Sep; 607():121025. PubMed ID: 34418472
[TBL] [Abstract][Full Text] [Related]
12. DissolvIt: An In Vitro Method for Simulating the Dissolution and Absorption of Inhaled Dry Powder Drugs in the Lungs.
Gerde P; Malmlöf M; Havsborn L; Sjöberg CO; Ewing P; Eirefelt S; Ekelund K
Assay Drug Dev Technol; 2017; 15(2):77-88. PubMed ID: 28322599
[TBL] [Abstract][Full Text] [Related]
13. Solidification of nanosuspensions for the production of solid oral dosage forms and inhalable dry powders.
Malamatari M; Somavarapu S; Taylor KM; Buckton G
Expert Opin Drug Deliv; 2016; 13(3):435-50. PubMed ID: 26764574
[TBL] [Abstract][Full Text] [Related]
14. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
[TBL] [Abstract][Full Text] [Related]
15. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.
Mann J; Dressman J; Rosenblatt K; Ashworth L; Muenster U; Frank K; Hutchins P; Williams J; Klumpp L; Wielockx K; Berben P; Augustijns P; Holm R; Hofmann M; Patel S; Beato S; Ojala K; Tomaszewska I; Bruel JL; Butler J
Mol Pharm; 2017 Dec; 14(12):4192-4201. PubMed ID: 28737403
[TBL] [Abstract][Full Text] [Related]
16. Respiratory Tract: Structure and Attractions for Drug Delivery Using Dry Powder Inhalers.
ElKasabgy NA; Adel IM; Elmeligy MF
AAPS PharmSciTech; 2020 Aug; 21(7):238. PubMed ID: 32827062
[TBL] [Abstract][Full Text] [Related]
17. Development of an Aerosol Dose Collection Apparatus for In Vitro Dissolution Measurements of Orally Inhaled Drug Products.
Price R; Shur J; Ganley W; Farias G; Fotaki N; Conti DS; Delvadia R; Absar M; Saluja B; Lee S
AAPS J; 2020 Feb; 22(2):47. PubMed ID: 32060670
[TBL] [Abstract][Full Text] [Related]
18. Searching for physiologically relevant in vitro dissolution techniques for orally inhaled drugs.
Radivojev S; Zellnitz S; Paudel A; Fröhlich E
Int J Pharm; 2019 Feb; 556():45-56. PubMed ID: 30529665
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of extemporaneously compounded immediate-release capsules with premixed excipients, based on the biopharmaceutics classification system (BCS) of the drugs.
Pinheiro VA; Danopoulos P; Demirdjian L; Nogueira RJ; Dubois F
Int J Pharm Compd; 2013; 17(5):424-31. PubMed ID: 24459788
[TBL] [Abstract][Full Text] [Related]
20. Dosing considerations for inhaled biologics.
Ferrati S; Wu T; Kanapuram SR; Smyth HDC
Int J Pharm; 2018 Oct; 549(1-2):58-66. PubMed ID: 30053488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
